A Single-arm, Open-label, Phase III Trial to Evaluate the Safety and Tolerability of Intra-articular Injections of RTX-GRT7039 in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Resiniferatoxin (Primary)
Indications Osteoarthritis
Focus Adverse reactions; Registrational
Sponsors Grunenthal

Most Recent Events

21 Mar 2025 Planned End Date changed from 28 Aug 2025 to 16 May 2025.
21 Mar 2025 Planned primary completion date changed from 28 Aug 2025 to 16 May 2025.
20 Dec 2024 Planned primary completion date changed from 25 Aug 2025 to 28 Aug 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight